Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Phase 1, Single-dose Study to Evaluate the Pharmacokinetics of Elafibranor 120 mg in Adult Subjects With Hepatic Impairment and Adult Healthy Control Subjects

Next Previous
Trial Profile

An Open-label, Phase 1, Single-dose Study to Evaluate the Pharmacokinetics of Elafibranor 120 mg in Adult Subjects With Hepatic Impairment and Adult Healthy Control Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elafibranor (Primary)
  • Indications Liver disorders; Non-alcoholic steatohepatitis; Primary biliary cirrhosis
  • Focus Pharmacokinetics
  • Sponsors Genfit

    • Most Recent Events

    • 15 Nov 2021 Results assessing effect of affects the pharmacokinetics, safety, and tolerability of elafibranor in hepatic impairment patients, presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases.
    • 02 Nov 2021 According to Genefit SA Media Release, data from this trial will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2021
    • 02 Nov 2021 Results published in the Genefit SA Media Release
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top